Lv D - Search Results

1

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.

Song Z, Li Y, Chen S, Ying S, Xu S, Huang J, Wu D, Lv D, Bei T, Liu S, Huang X, Xie C, Wu X, Fu J, Hua F, Wang W, Xu C, Gao C, Cai S, Lu S, Zhang Y. Song Z, et al. Among authors: lv d. BMC Med. 2022 Feb 1;20(1):42. doi: 10.1186/s12916-022-02245-z. BMC Med. 2022. PMID: 35101045 Free PMC article. Clinical Trial.

2

Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.

Xu H, Lv D, Meng Y, Wang M, Wang W, Zhou C, Zhou S, Chen X, Yang H. Xu H, et al. Among authors: lv d. Ann Palliat Med. 2020 Mar;9(2):298-307. doi: 10.21037/apm.2020.01.16. Epub 2020 Feb 18. Ann Palliat Med. 2020. PMID: 32075401 Free article.

3

Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.

Li H, Wang J, Zhang G, Li Y, Lin L, Yang H, Zhou J, Zhang L, Lv D. Li H, et al. Among authors: lv d. J Thorac Dis. 2020 Mar;12(3):550-557. doi: 10.21037/jtd.2019.12.122. J Thorac Dis. 2020. PMID: 32274120 Free PMC article.

4

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.

Zheng J, Cao H, Li Y, Rao C, Zhang T, Luo J, Lv D, Zhu Y, Zhou J, Zhou J. Zheng J, et al. Among authors: lv d. Lung Cancer. 2020 Sep;147:130-136. doi: 10.1016/j.lungcan.2020.07.016. Epub 2020 Jul 16. Lung Cancer. 2020. PMID: 32702569

5

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.

Shi Y, Hu X, Zhang S, Lv D, Wu L, Yu Q, Zhang Y, Liu L, Wang X, Cheng Y, Ma Z, Niu H, Wang D, Feng J, Huang C, Liu C, Zhao H, Li J, Zhang X, Jiang Y, Gu C. Shi Y, et al. Among authors: lv d. Lancet Respir Med. 2021 Aug;9(8):829-839. doi: 10.1016/S2213-2600(20)30455-0. Epub 2021 Mar 26. Lancet Respir Med. 2021. PMID: 33780662 Clinical Trial.

6

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study.

Song Z, Lv D, Chen S, Huang J, Wang L, Xu S, Chen H, Wang G, Lin Q. Song Z, et al. Among authors: lv d. Front Oncol. 2021 May 7;11:657283. doi: 10.3389/fonc.2021.657283. eCollection 2021. Front Oncol. 2021. PMID: 34026634 Free PMC article.

7

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.

Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C. Shi Y, et al. Among authors: lv d. Cancer Commun (Lond). 2021 Sep;41(9):889-903. doi: 10.1002/cac2.12179. Epub 2021 Jun 29. Cancer Commun (Lond). 2021. PMID: 34184418 Free PMC article. Clinical Trial.

8

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.

Wang P, Li Y, Lv D, Yang L, Ding L, Zhou J, Hong W, Chen Y, Zhang D, He S, Zhou J, Wang K. Wang P, et al. Among authors: lv d. Signal Transduct Target Ther. 2021 Nov 1;6(1):374. doi: 10.1038/s41392-021-00773-3. Signal Transduct Target Ther. 2021. PMID: 34719670 Free PMC article. Clinical Trial.

9

Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.

Song Z, Lv D, Chen SQ, Huang J, Li Y, Ying S, Wu X, Hua F, Wang W, Xu C, Bei T, Gao C, Sun Z, Zhang Y, Lu S. Song Z, et al. Among authors: lv d. Clin Cancer Res. 2022 Feb 1;28(3):461-467. doi: 10.1158/1078-0432.CCR-21-2936. Epub 2021 Nov 9. Clin Cancer Res. 2022. PMID: 34753778 Clinical Trial.

10

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.

Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Yang Z, Shi W, Zou J, Zhou C; CameL-sq Study Group. Ren S, et al. Among authors: lv d. J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16. J Thorac Oncol. 2022. PMID: 34923163 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,492 results

Search Page